期刊文献+

老年男性下肢动脉硬化与骨密度的相关性研究 被引量:3

The relationship between arteriosclerosis of lower extremity and osteoporosis in elderly male patients
暂未订购
导出
摘要 目的探讨老年男性原发性骨质疏松(osteoporosis,OP)与下肢动脉硬化之间的关系。方法采用彩超检测130例老年男性下肢动脉血管壁内膜厚度、血管内径、斑块、血流情况,按病变严重程度分为无病变组,轻度病变组,中重度病变组。测定血脂、骨代谢指标、采用双能X线吸收仪(dual-energy X-ray absorptiometry,DXA)测定骨密度(bonemineral density,BMD),比较三组间的骨密度、骨代谢指标、血脂差异。结果无病变组骨密度、血清骨碱性磷酸酶均高于轻度病变组和中重度病变组,无病变组总胆固醇及低密度脂蛋白低于中重度病变组,无病变组高密度脂蛋白、甘油三脂高于中重度病变组。结论老年男性下肢动脉硬化是骨密度下降的危险因素,脂代谢参与两者发病。 Objective To discuss the relationship between osteoporosis and arteriosclerosis of lower-extremity in elderly male patients. Methods The arterial wall endometrial thickness, luminal diameter, plaque and blood flow of lower -extremity was dectected by ultrasound in 130 male elderly patients. And the patients were divided into 3 groups (non-arte- riosclerosis group, mild group, moderate/severe group) according to the severity of lower-extremity artery disease, which the blood lipid and bone metabolic parameters were measured. Then the bone mineral density (Bone mineral density, BMD) was measured by dual energy X ray absorptiometry (DXA, GE Lunar, US). At last, we compared the difference of the BMD, bone metabolic parameters, and serum lipid in these 3 groups. Results In the non-arteriosclerosis group, the BMD and bone alkaline phosphatase (BALP) were both higher than other 2 groups (mild group and moderate/severe group), the total cholesterol and low density lipoprotein (LDL) were lower than the moderate/severe group, and the High density lipoprotein (HDL) and triglycerides were higher than moderate/severe group. Conclusion The atheroselerosis of lower extremity is one of the risk factor in bone mass decrease in elderly male patients, and lipid metabolism may be involved in these two diseases.
出处 《中国现代医生》 2012年第3期56-58,共3页 China Modern Doctor
关键词 骨质疏松:动脉硬化 骨密度 Osteoporosis Arteriosclerosis Bone density
  • 相关文献

参考文献14

  • 1Sinnott B,Syed I,Sevrukov A,et al. Coronary calcification and steoporosis in men and postmenopausal women are independent processes associated with aging[J]. Calcif Tissue Int, 2006,78 (4) : 195-202.
  • 2Bauer DC,Mundy GR,Jamal SA,et al. Use of statins and fracture:re- suits of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials[J]. Arch Intern Med,2004,164 (2): 146-152.
  • 3潘长玉,高妍,袁申元,李光伟,王姮,陆菊明,李俊来,杨国庆,张俊清,陈铭,朱良湘,刘效慈,肖平,张学文,肖新华,李文慧,姜育新.2型糖尿病下肢血管病变发生率及相关因素调查[J].中国糖尿病杂志,2001,9(6):323-326. 被引量:510
  • 4Shaffer JR,Kammerer CM,Rainwater DL,et al. Decreased bone mineral density is correlated with increased subclinical atherosclerosis in older, but not younger,Mexican American women and men :the San Antonio Family Osteoporosis Study[J]. Calcif Tissue Int,2007,81:430-441.
  • 5Laroche M,Moulinier L,Leger P,et al. Bone mineral decrease in the leg with unilateral chronic occlusive arterial disease[J]. Clin Exp Rheumatol, 2003,21 ( 1 ) : 103-106.
  • 6Tanko LB,Christiansen C,Cox DA,et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women[J]. J Bone Miner Res,2005,20( 11 ) : 1912-1920.
  • 7Hofbauer LC,Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis[J]. Arthritis Rheum, 2001,44 (2) : 253-259.
  • 8许勇,杨桦,乔建瓯,李西华,严兰珍,王龙,徐国江,费俭,傅继粱,王铸钢.骨保护素(Opg)基因敲除小鼠发生高转换型骨质疏松和动脉钙化(英文)[J].生物化学与生物物理进展,2007,34(3):260-266. 被引量:26
  • 9Ovehinnikova O,Gylfe A,Bailey L,et al. Osteoprotegerin promotes fibrous cap formation in atheroselerotie lesions of ApoE-deficient micebrief report[J]. Arterioseler Thromb Vase Biol,2009,29(10) : 1478-1480.
  • 10Min H,Morony S,Sarosi I,et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis[J]. J Exp Med, 2000,192(4) :463-474.

二级参考文献18

  • 1中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(F03):1-3. 被引量:325
  • 2[1]Amos AF, McCarty PJ, Zimmet P. The rising global burden of diabetes and its complications. Estimates and projections to the year 2010,Diab Med,1997,7:85.
  • 3[4]Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers:The world health organization multinational study of vascular disease in diabetics. Diabetologia. 1985,28:615~640.
  • 4Tolar J,Teitelbaum S L,Orchard P J.Osteopetrosis.N Engl J Med,2004,351:2839~2849
  • 5Doherty T M,Fitzpatrick L A,Inoue D,et al.Molecular,endocrine,and genetic mechanisms of arterial calcification.Endocr Rev,2004,25:629~672
  • 6Schulz E,Arfai K,Liu X,et al.Aortic calcification and the risk of osteoporosis and fractures.J Clin Endocrinol Metab,2004,89:4246~4253
  • 7Bucay N,Sarosi I,Dunstan C R,et al.Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev,1998,12:1260~1268
  • 8Min H,Morony S,Sarosi I,et al.Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembing osteoclastogenesis.J Exp Med,2000,192:463~474
  • 9Hofbauer L C,Schoppet M.Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular disease.JAMA,2004,292:490~495
  • 10Nakamura,Udagawa N,Matsuura S,et al.Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.Endocr,2003,144:5441 ~5449

共引文献550

同被引文献13

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部